Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

LONDON, April 13, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce that its wireless, wearable LEAF Patient Monitoring System has  monitored more than 60,000 patients with over 7 million hours of use, helping to reduce the economic and human costs of pressure injuries. While rates of other hospital-acquired conditions have declined in the US in recent years, hospital acquired pressure injury (HAPI) rates have continued to increase1, leading to an average incremental cost of $21,767 per patient impacted.2 In a randomized clinical trial conducted using the LEAF System, results showed that HAPI odds were reduced by 73%3*, an impact which could help eliminate up to $39 billion in avoidable HAPI costs if expanded nationally.1,2 "We're proud that the LEAF System has reached this major milestone while driving improved patient outcomes and economic savings to healthcare systems.

Seven million hours of patient data shows that Smith+Nephew's wireless, wearable LEAF™ Patient Monitoring System helps prevent hospital-acquired pressure injuries

LONDON, March 25, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a marketing collaboration with Movendo Technology (Genoa, Italy) that will add personalised robotic patient rehabilitation capability to Smith+Nephew's Real Intelligence enabling technology solutions, creating a fully digitised patient pathway from the pre-op stage to post-rehab phase. The collaboration has launched in Europe and will expand to other regions in the near future.

Smith+Nephew adds Movendo Technology's patient rehabilitation solution to Real Intelligence digital ecosystem

LONDON, March 18, 2021 /PRNewswire/ -- Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped to significantly reduce dressing change frequency and weekly dressing costs, while improving treatment satisfaction for clinicians and patients in a community setting.*1 At week 4, compared with previous dressings, ALLEVYN LIFE Dressings significantly reduced mean weekly dressing change frequency by 47.1%* 1 and mean weekly dressing costs by 58.7%.

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings halved change frequency, significantly reduced cost and improved treatment satisfaction in real-world study

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2020 Results - Earnings Call Transcript

Medical device maker Smith & Nephew plc (NYSE: SNN) slips in the premarket after reporting a slump in revenues and profits. Full-year 2020 revenue fell 11.2% Y/Y to $4.6 billion, and operating profit dropped over 60% to $295 million.

Smith & Nephew Maintains Dividend For 2021 Despite Q4 Earnings Hit By COVID-19; Shares Drop

Smith & Nephew PLC (LON:SN) saw its shares slide in early deals as it caught the market on the hop with a disappointing set of results. Shares in the wound care and knee & hip implants specialist were down 7.3% at 1,453p, making them the worst performers in the FTSE 100 after it reported a 7.1% underlying fall in revenue for the final quarter of 2020 to US$1,326mln from US$1,407mln the year before.

Smith & Nephew suffers nasty fall

Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.

Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging

LONDON, Jan. 27, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced the odds of surgical site...

Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System again shown to significantly reduce surgical site complications

Activision Blizzard

ALPS Barron's 400 ETF

Siren Nasdaq NexGen Economy ETF

Roku

Twitter

UnitedHealth Group

The rally in 2020 may mean many stocks are not cheap any more, but long-term investors can still find robust stocks to buy in a bull market The post 7 Stocks to Buy for a Continued Run with the Market Bulls appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

7 Stocks to Buy for a Continued Run with the Market Bulls

Let's see if Smith & Nephew plc (SNN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Is Smith & Nephew (SNN) a Suitable Stock for Value Investors?

Smith & Nephew has a solid, growing business which will grow with market growth as well as by acquisition. It has a decent dividend payment history.

Smith & Nephew: A Long-Term Buy And Hold In Medical Devices

Bristol-Myers

CVS Health

Intuitive Surgical

Allscripts Healthcare Solutions

SPDR S&P Pharmaceuticals ETF

Teladoc

These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election. The post 7 Healthcare Stocks That Can Survive Massive Reform appeared first on InvestorPlace.

7 Healthcare Stocks That Can Survive Massive Reform

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q3 2020 Results - Earnings Call Transcript

In an announcement on Thursday, Smith & Nephew plc (LON: SN) said its underlying revenue is expected to see a 4% decline in the fiscal third quarter. Underlying revenue does not account for non-recurring and other exceptional items.

Smith & Nephew forecasts a 4% decline in third-quarter underlying revenue

Integra LifeSciences Holdings

Smith & Nephew 
        SNN, 
        +2.16% 
      
        SN, 
        -0.91% 
       said it's buying the extremity orthopedics unit of Integra LifeSciences 
        IART, 
        -0.40% 
       for $240 million in cash. Smith & Nephew said the deal will provide entry into the shoulder replacement and foot and ankle segment.

Smith & Nephew buying Integra LifeSciences unit

LONDON, Sept. 2, 2020 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its NOVOSTITCH PRO Meniscal Repair System in Europe after successfully receiving CE mark certification.

Smith+Nephew launches NOVOSTITCH™ PRO Meniscal Repair System in Europe

With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.

Smith+Nephew Unveils Digital Platform to Boost Patient Care

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q2 2020 Results - Earnings Call Transcript

Stryker

Zimmer Biomet Hlds

The pandemic hit Zimmer, Smith+Nephew, and Stryker hard -- but they'll soon rise again.

3 Cheap Surgical Stocks to Buy Now Before They Bounce Back

Becton, Dickinson and Co.

Ford Motor Company

Fiat Chrysler

General Motors

Johnson & Johnson

Medtronic

NuVasive

Royal Philips

ResMed

Tesla

Wright Medical Group

Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Can Medical Device Stocks Help Rebuild Your Portfolio?

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2019 Results - Earnings Call Transcript

The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.

Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries

Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.

Smith & Nephew's Study Outcomes for REGENETEN Encouraging

Its chief executive's sudden exit sent the stock reeling.

Why Shares of Smith & Nephew Fell 10.2% in October

Smith & Nephew PLC (SNN) Management on Q3 2019 Results - Earnings Call Transcript

News for Smith & Nephew Stock (SNN)